Business Context and Reporting Period
This Form 8-K Current Report, dated April 24, 2025, details material definitive agreements entered into by Oramed Pharmaceuticals Inc. (the "Company") and its wholly-owned subsidiary, Oramed Ltd. The report covers events occurring on April 24, 2025, with the closing of the primary transaction occurring on April 28, 2025.
Key Financial Metrics and Transaction Details
- Investment in Alpha Tau Medical Ltd.: Oramed purchased 14,110,121 ordinary shares of Alpha Tau Medical Ltd. ("Alpha Tau") at a price of $2.612 per share.
- Total Purchase Price: Approximately $36.9 million (prior to Alpha Tau's deduction of estimated offering expenses).
- Strategic Services Fee: Alpha Tau agreed to pay Oramed a non-refundable fee of $3.0 million for strategic investor relations and public relations services.
- Fee Payment Schedule: $500,000 payable upon execution; the remaining $2.5 million payable in five equal installments every six months.
- Warrant Compensation: Subject to shareholder approval, Alpha Tau agreed to issue warrants to purchase up to 3,237,000 ordinary shares (2,390,000 at $3.90/share and 847,000 at $3.474/share).
Material Changes and Governance Rights
The filing discloses a significant change in Oramed's asset base and strategic positioning through the acquisition of a substantial equity stake in Alpha Tau. Key governance provisions include:
- Board Representation: Oramed has the right to nominate two directors to the Alpha Tau Board of Directors within three months of the closing date.
- Board Size Restriction: Alpha Tau cannot increase its Board size above eight members without Oramed's prior written consent, provided Oramed remains the largest shareholder or owns at least 10% of outstanding shares.
- Service Agreement Term: The Strategic IR/PR Services Agreement has a three-year term with limited termination rights.
Outlook, Risks, and Contingencies
The filing notes that the issuance of the IR/PR Warrants is contingent upon approval by Alpha Tau's shareholders at its upcoming Annual General Meeting. The warrants are exercisable immediately upon issuance and expire 2.5 years after the effective date of the Strategic Services Agreement. Alpha Tau has agreed to register the shares issuable upon exercise of these warrants for resale within 60 to 120 days, depending on SEC review status. The filing explicitly states that the Company undertakes no obligation to update or supplement the information provided.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $36.9 million cash outflow in subsequent financial statements.
- Confirm the outcome of Alpha Tau's Annual General Meeting regarding the approval of the IR/PR Warrants.
- Monitor the registration status of the shares underlying the warrants for resale eligibility.
- Review the impact of the $3.0 million service fee on Oramed's future revenue recognition.
- Assess the strategic rationale for the investment and the potential for future board influence over Alpha Tau.